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ABSTRACT 
This commentary on my publications concerns the molecular functions of the androgen 
receptor (AR) and Brain Expressed X-Linked 2 (BEX2) in breast cancer. It is notable that 
the presented articles have made significant contributions to the fields of cancer 
genomics, cancer biology and experimental therapeutics with broad applications in 
breast cancer and other malignancies. The first chapter outlines gene expression 
microarray studies and explains genomic data resulting in the discovery of BEX2 in 
breast cancer. Chapter two elaborates on my publications regarding the molecular 
functions of BEX2 in promoting breast cancer cell growth and survival by modulating the 
mitochondrial apoptotic pathway and G1 cell cycle. In addition, this chapter explains the 
cross-talk between BEX2 and the NF-κB, c-Jun/JNK and ErbB2 pathways and provides 
a summary of my studies on the association of BEX2 expression with clinical and 
pathological features in breast tumors. Chapter three presents my publications on a 
cross-talk between AR and ErbB2-ERK signaling in estrogen receptor-negative breast 
cancer. Furthermore, this chapter summarizes in vitro and in vivo studies on the 
combined inhibition of AR and ErbB2-ERK signaling as a therapeutic strategy in 
molecular apocrine breast cancer. In addition, this chapter discusses the molecular 
functions of the Prolactin-Induced Protein, an established target gene of AR, in invasion, 
cell cycle and adhesion across different subtypes of breast cancer. Chapter four details 
my studies on the transcriptional network and novel target genes of AR in breast cancer. 
This chapter includes findings on AR-mediated regulation of Factor VII and the discovery 
of a novel protein, SRARP (C1orf64), as an AR coregulator with corepressor functions 
in breast cancer. In conclusion, chapter five provides a discussion on the impact of my 
publications in advancing different fields of cancer research and the emerging clinical 
applications of the presented studies in breast cancer.  
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CHAPTER 1: GENOMIC STUDIES IN BREAST CANCER 
1.1 Methodology for gene expression microarray  
I started my research on gene expression microarrays as a postdoctoral fellow at the 
University of Cambridge in October 2002. The aim of this project was to conduct gene 
expression profiling in human breast tumors. At the time, gene expression profiling was 
a relatively new technology and the methodologies used in this field were not adequately 
optimized. Therefore, I carried out studies in optimization of RNA purification and 
labelling techniques for expression microarray applications and published the results (1, 
2).  
Purification of amplified RNA (aRNA) is a key step in preparing labelled probes for 
expression microarrays. Generation of aRNA for expression microarrays is performed 
by global amplification using in vitro transcription, which involves multiple purification 
steps. A major concern during these steps is the exclusion of transcripts based on size, 
leading to selection bias in subsequent expression microarray analysis (1). In view of 
this, I investigated various purification methods to identify the best approach for each 
step in the generation of aRNA using indirect labelling (1). The identified purification 
protocol provides good yield, purity, coupling efficiency and preservation of different-
sized transcripts. This process also generates labelled targets for microarray 
hybridization with an optimal coefficient of repeatability (1).  
Another source of variability in expression microarray analysis is the quantity of 
fluorescent dye used per experiment. At the time of this study, there was insufficient data 
to determine the optimal labelled dye requirements for microarray applications. 
Therefore, I addressed this question and demonstrated that the quantity of Cy3 dye 
affects expression microarray results performed on tumor specimens (2). Notably, this 
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study showed that signal-to-noise ratios and coefficients of variation are significantly 
improved by increasing Cy3 levels in indirect aRNA labelling. Therefore, optimal dye 
levels reduce variability and improve reliability of expression microarray experiments.  
Data presented in (1) and (2) were critical for subsequent expression microarray studies 
and the discovery of BEX2 (Brain Expressed X-Linked 2) as a novel gene in breast 
cancer. Notably, BEX2 has a small transcript size with an open reading frame (ORF) of 
460 bp and a 160 aa protein product. Consequently, the application of optimized 
purification techniques that preserved small transcripts contributed to the identification 
of the BEX2 gene in breast cancer. 
1.2 Gene expression profiling in primary breast tumors 
Following optimization of the microarray methodology, gene expression profiling in 135 
primary (early-stage) breast tumors was undertaken using a cohort of frozen tumor 
samples. The long follow-up and conservative use of adjuvant therapy made this cohort 
ideal for a prognostic study. The results of expression microarray analysis and a robust 
prognostic signature obtained from this study were published (3). RNA amplification, 
purification and labelling methods were carried out as previously described (1, 2). 
Oligonucleotide microarrays containing 22,575 features were used for this study (Agilent 
Human 1A 60-mer Oligo Microarray) and the expression data was deposited at 
MIAMExpress at the EBI with accession number E-UCon-1. I performed paired dye-
reversal hybridizations in 127 samples and one-way hybridization in eight samples owing 
to limited amount of RNA, in addition to a second set of 45 biological replicate 
hybridizations in 24 samples (3).  
The expression analysis in the above cohort identified a prognostic signature of 70 
genes. This signature was further validated in two independent external data sets, which 
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collectively contained a total of 715 patients (3). A common prognostic module of 29 
genes that was associated with survival in both our cohort and the two external data sets 
was identified. Interestingly, the 29 overlapping genes were consistently overexpressed 
in poor prognosis tumors and these signature genes were connected to cancer 
development functions such as oncogenesis, cell cycle progression and chromosome 
dynamics (3). It is notable that the gene expression data obtained from this study was 
applied to identify novel genes with a differential expression pattern in breast cancer, 
resulting in the identification of the BEX2 gene in this disease. 
1.3 Discovery of BEX2 in breast cancer using expression profiling     
Genes that have an important biological function in cancer generally show a differential 
expression pattern with a relatively higher expression in a subset of tumors. It is notable 
that in expression microarray analysis of breast tumors, a two-channel platform (Cy3 and 
Cy5 dyes) was utilized, which included a dye-reversal design with a subset of tumor 
samples applied as the reference pool (3). Therefore, this study provided an ideal 
dataset to investigate genes having a differential expression pattern in breast cancer that 
can act as classifiers.  
To achieve this aim, further analysis of expression microarray data identified BEX2 as 
the gene with the highest frequency of significant log2 ratios (p< 0.05) across the studied 
cohort of breast tumors (4). This finding indicated that the expression of BEX2 varied 
significantly across most tumor samples. Furthermore, cancer outlier profile analysis 
(COPA), an established methodology to identify biologically relevant genes (Tomlins et 
al., 2005), showed that BEX2 and its close homologue, BEX1, ranked among the top 
genes with an outlier profile in the dataset (4). In addition, BEX2 appeared to have a 
relatively higher expression in estrogen receptor-positive (ER+) tumors.  
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The mutual presence of BEX2 and BEX1 in COPA analysis was striking and led to further 
investigation of their expression profiles. BEX2 expression relative to the common 
reference pool separated the tumors into two significantly different (p< 1 x 10-5) groups 
with BEX2 overexpression and underexpression detected in and 20 and 115 samples, 
respectively. BEX1 expression also varied significantly between the two groups (p< 1 x 
10-5), reflecting a strong correlation between BEX2 and BEX1 expression patterns 
(Pearson correlation coefficient (CC) = 0.94). In addition, quantitative real time-PCR 
(qRT-PCR) was performed on a subset of breast tumors and demonstrated a strong 
correlation between the microarray and qRT-PCR data for BEX2 expression (4).  
The next question asked was, if there were a group of genes that significantly correlated 
with BEX1 and BEX2 (BEX+ cluster). A correlation analysis and Monte-Carlo simulation 
identified 35 genes with significant correlations to the expression of BEX1 and BEX2 in 
breast tumors (4). Furthermore, to identify genes that could differentiate between tumors 
expressing high levels of BEX genes from the remainder of cases, the samples were 
divided into two groups based on the expression ratios of BEX2 (BEX+ log2 > 0; BEX- 
log2 < 0). Supervised analysis using a class prediction algorithm generated an optimal 
classifier consisting of 37 genes with a correct classification rate of 85% (4).  
To validate the findings, further supervised analysis using t-test/ANOVA and significance 
analysis of microarray (SAM) was conducted. The results showed that approximately 2/3 
of the genes overlap among all supervised methods and with the BEX+ cluster. These 
findings indicate a distinct expression signature differentiating BEX+ and BEX- samples, 
which is reproducible using different methods of analysis. To gain further insights into 
the potential functional significance of the BEX-signature, the Ingenuity Pathways 
Analysis software was employed and a significant enrichment of the BEX-signature for 
developmental, apoptosis and cell proliferation functions was found (4).  
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It is notable that BEX2 belongs to a family of genes, including BEX1, NGFRAP1 (alias 
BEX3), BEXL1 (alias BEX4) and NGFRAP1L1 (alias BEX5), which at the time of our 
study were mainly identified as developmental genes expressed in brain tissue (Alvarez 
et al., 2005; Brown and Kay, 1999). Therefore, our genomic studies for the first time 
revealed BEX2 as a novel classifier in breast cancer that is associated with a gene-
signature enriched for key cellular functions. In view of the gene ontology categories 
associated with the BEX-gene signature, the role of BEX2 in apoptosis and cell cycle 
was investigated in my subsequent studies.  
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CHAPTER 2: MOLECULAR FUNCTIONS OF BEX2 IN BREAST CANCER 
2.1 Molecular functions of BEX2 in apoptosis and cell cycle 
To investigate the molecular functions of BEX2, the transcriptional regulation of BEX2 in 
breast cancer cells was studied (4). It is notable that BEX2 is not amplified in breast 
cancer and is not expressed in normal breast tissue. Therefore, BEX2 overexpression is 
likely to be a result of transcriptional activation of this gene in breast tumors (4). 
Importantly, I found that both ceramide and Nerve Growth Factor (NGF) can markedly 
induce BEX2 expression in breast cancer cells (4). Ceramide is a mediator of apoptosis 
generated in response to apoptotic stimuli and may be studied by the treatment of cells 
using a synthetic ceramide analogue (C2), (El Yazidi-Belkoura et al., 2003). NGF is a 
neurotrophic factor that interacts with its receptor p75NTR and protects breast cancer 
cells against C2-mediated apoptosis through the activation of NF-κB pathway 
(Descamps et al., 2001).  
In view of these findings, it was hypothesized that BEX2 may have a function in 
ceramide-mediated apoptosis. This hypothesis was tested in breast cancer cell lines 
MCF-7 (ER+) and MDA-MB-231 (ER-) using BEX2 overexpression and siRNA-silencing 
experiments (4). Notably, BEX2 overexpression rescued cancer cells from C2-induced 
apoptosis (4). In addition, siRNA-silencing studies revealed that BEX2 expression is 
required for NGF-mediated anti-apoptotic response. Furthermore, BEX2 protects MCF-
7 cells against apoptosis induced by the anti-estrogen drug tamoxifen (4). In this process, 
tamoxifen-mediated apoptosis is significantly reduced by both NGF and BEX2 
overexpression. Treatment with the NF-κB inhibitor SN50 and BEX2-silencing remove 
the protective effects of BEX2 overexpression and NGF, respectively. These data 
indicate that activation of the NGF/BEX2 pathway inhibits tamoxifen-induced apoptosis 
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and this effect of BEX2 appears to be mediated through the NF-κB pathway. 
Furthermore, BEX2 expression regulates p50 NF-κB DNA binding and p65 NF-κB 
phosphorylation, suggesting that BEX2 functions upstream of NF-κB in modulating 
apoptosis (4).  
I continued my studies on the molecular functions of BEX2 in my independent research 
laboratory as a clinician-scientist faculty at The University of Queensland from December 
2007 to October 2012. Having shown that BEX2 is a part of the NGF/NF-κB pathway in 
breast cancer, I next characterized the therapeutic implications of this pathway (5). NGF 
effects on apoptosis and cell proliferation are mediated through p75NTR and p140TrkA 
receptors, respectively (Descamps et al., 2001). Notably, it was demonstrated that a 
p75NTR inhibitor Pep5, p140TrkA inhibitor K-252a and NF-κB inhibitor BAY11-7085 
have pro-apoptotic and anti-proliferative activities in breast cancer cells (5). A synergy in 
combining NGF receptor inhibitors with the conventional breast cancer treatments 
tamoxifen and taxol was also demonstrated (5). These findings suggest that the inhibition 
of the NGF/NF-κB pathway is a potential treatment strategy in breast cancer. Therefore, 
as a part of the NGF/NF-κB pathway, BEX2 may present a novel therapeutic target in 
this disease.  
My laboratory next carried out a comprehensive study to investigate a functional role for 
BEX2 in cell growth and survival using MCF-7 (ER+), T-47D (ER+), and MDA-MB-231 
(ER-) breast cancer cell lines (6). The effect of BEX2-siRNA silencing on the induction 
of apoptosis was examined using an Annexin V-flow cytometry assay (6). Notably, there 
was a significant increase at the baseline level of apoptosis following BEX2-silencing in 
all three cell lines (6). This effect was most prominent in MDA-MB-231 cells, which 
demonstrated a 5-fold increase in the level of apoptosis. Furthermore, BEX2-silencing 
significantly sensitized all the cell lines to the pro-apoptotic effects of ceramide, NF-κB 
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inhibitor BAY11-7085, chemotherapeutic agent adriamycin and mitochondrial pro-
apoptotic agent staurosporine (STS), (6). Therefore, BEX2 expression protects breast 
cancer cells against apoptosis (see Figure 1).  
Subsequent experiments examined whether the effect of BEX2 on apoptosis is mediated 
through the mitochondrial intrinsic pathway (6). This was first studied by a mitochondrial 
permeability transition (MPT)-based apoptosis assay that detects a change in the 
mitochondrial transmembrane potential by fluorescent staining. MPT assays showed 
BEX2 overexpression has a protective effect against the induction of mitochondrial 
apoptosis by ceramide and STS (6). These findings were further confirmed by detecting 
a cytosolic release of cytochrome c from mitochondria following BEX2-siRNA silencing. 
To investigate an underlying mechanism for the protective effect of BEX2 against 
mitochondrial apoptosis, a potential role for BEX2 in the regulation of Bcl-2 protein family 
was also explored. Importantly, BEX2-silencing modulated the phosphorylation and 
expression of key Bcl-2 family members in the direction of promoting a pro-apoptotic 
imbalance in breast cancer cells (6). For instance, BEX2-silencing led to a significant 
reduction in the phosphorylation level of anti-apoptotic protein Bcl-2 and an increase in 
the expression of pro-apoptotic genes BAK1 and PUMA.  
Moreover, the effect of BEX2 expression on cell cycle was examined using flow 
cytometry analysis (6). These studies revealed a significant increase in the G1 cell 
population after BEX2-silencing in all three breast cancer lines suggesting a G1 cell cycle 
arrest, which was associated with a reduction in cyclin D1 expression and an increase 
in p21 levels. Notably, cyclin D1 and p21 are key proteins that promote and inhibit the 
G1 progression, respectively (Kim et al., 2000; Wang et al., 2007). Therefore, it appears 
that BEX2 expression is required for the G1 phase progression in breast cancer cells 
(see Figure 1). 
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Finally, to elucidate a biochemical mechanism for the effect of BEX2 on protein 
phosphorylation, the possibility of BEX2 regulation of PP2A (protein phosphatase 2A) 
activity was investigated. This hypothesis was suggested due to ceramide being a 
modulator of PP2A (Ruvolo et al., 1999) and our findings demonstrating a strong 
interplay between BEX2 and ceramide signaling. Notably, BEX2-silencing significantly 
increased PP2A activity by 1.5-fold, indicating that BEX2 expression regulates PP2A 
phosphatase activity in breast cancer cells (6). Therefore, the regulation of PP2A 
provides a possible underlying mechanism for BEX2-mediated cellular effects in breast 
cancer (see Figure 1).  
Altogether these studies suggest that BEX2 expression promotes cell growth and 
survival in breast cancer cells and has a pro-oncogenic function in this disease. 
 
Figure 1. A schematic diagram of BEX2 interactions with the mitochondrial apoptosis 
pathway and G1 cell cycle. Green arrow: stimulatory effect; Red crossed-line: inhibitory 
effect.  
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2.2 BEX2 cross-talk with NF-κB, c-Jun/JNK and ErbB2 signaling                                 
To better understand the molecular functions of BEX2, my laboratory next investigated 
the underlying mechanisms for BEX2 transcriptional activation and the signaling cross-
talk involved in this process and published the results (7, 8). Bioinformatics analysis of 
the BEX2 promoter identified six AP-1/c-Jun and three NF-κB/RelA putative binding sites 
(7). Next, luciferase reporter assays were performed to test the effect of candidate 
transcription factors on the activation of BEX2 promoter and direct DNA binding was 
assessed using Chromatin Immunoprecipiation (ChIP) assay. These experiments 
demonstrated that BEX2 is a target gene for c-Jun and p65/RelA in breast cancer cells 
and in order to bind and activate the BEX2 promoter, c-Jun and p65 require 
phosphorylation at Ser63 and Ser468 sites, respectively (7).  
The fact that BEX2 transcription is strongly regulated by c-Jun and p65 raises the 
question whether BEX2 has a role in the cellular activities mediated by these proteins. 
Furthermore, we have previously demonstrated that BEX2 expression is necessary for 
NGF-mediated activation of NF-κB (4). To investigate the effect of BEX2 on p65 
activation we assessed the nuclear localization of p65 following BEX2 overexpression in 
breast cancer cells (7). Notably, BEX2 overexpression increased the percentage of 
nuclear-only p65 staining by 3-fold and this effect was completely reversed with the 
addition of IкBα phosphorylation inhibitor BAY11-7082. These data suggest that BEX2 
overexpression increases the nuclear localization of p65 in a process that requires IκBα 
phosphorylation. The observed effect of BEX2 on p65 nuclear transport can be explained 
by the fact that BEX2 expression regulates the phosphorylation of p65 and IκBα. In this 
respect, BEX2-silencing results in a reduction of phospho-p65/total-p65 and phospho-
IκBα/total-IκBα ratios by 0.65- and 0.6-fold, respectively and also inhibits ceramide-
mediated induction of p65 DNA binding (7).   
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To further investigate cross-regulation between BEX2 and its transcription factors, the 
effect of BEX2 expression on the phosphorylation of c-Jun (Ser63) was subsequently 
examined in breast cancer cells (7). Notably, BEX2-silencing led to a marked reduction 
in c-Jun phosphorylation by 3 to 8-fold as well as a 2.4-fold decrease in the activity of c-
Jun-N-terminal Kinase (JNK). These findings indicate that BEX2 expression is necessary 
for c-Jun phosphorylation and JNK kinase activity. Moreover, using the stably transfected 
c-Jun lines generated in MCF-7 cells (c-Jun+), it was shown that BEX2 expression is 
required for c-Jun-mediated induction of cyclin D1 and cell proliferation. In addition, 
BEX2-silencing increased PP2A activity in c-Jun+ stable lines, presenting further 
evidence for BEX2-mediated regulation of PP2A (7). 
Collectively, these results suggest that BEX2 has a functional cross-talk with c-Jun and 
p65/RelA in breast cancer (see Figure 2). In this feedback process, BEX2 is a target 
gene for c-Jun and p65/RelA. BEX2, in turn, regulates the phosphorylation of c-Jun, p65 
and IκBα in addition to JNK kinase activity. Furthermore, BEX2-mediated inhibition of 
PP2A provides a possible mechanism for these functional effects by regulating the 
phosphorylation and activation of proteins in the NF-κB and c-Jun/JNK pathways.  
 
Figure 2. BEX2 interplay with c-Jun, p65 and PP2A. Green arrow: stimulatory effect; 
Red crossed-line: inhibitory effect. P: phosphorylated protein.  
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A feedback loop between BEX2 and ErbB2 is another biologically significant interplay 
that was revealed as a result of these studies (8). Following the generation and validation 
of a rabbit polyclonal BEX2 antibody, BEX2 protein expression was examined on a large 
cohort of breast tumors using immunohistochemistry (IHC) staining. Notably, BEX2 
positive tumors identified a subset of breast cancers with the overexpression of ErbB2 
(ErbB2+) and phosphorylated c-Jun (ph-Jun+) proteins. This led me to investigate an 
underlying mechanism for the observed association between BEX2 expression and 
ErbB2+/ph-Jun+ status in breast cancer (8). Functional studies revealed that ErbB2 
overexpression leads to an induction of c-Jun and ph-Jun expression in breast cancer 
cells. Furthermore, ErbB2-overexpressing cells demonstrated a 2-fold increase in BEX2 
protein expression compared to the control and this effect was abrogated by the co-
transfection of TAM67 (dominant negative c-Jun) or c-Jun siRNA-silencing in ErbB2-
transfected cells (8). These findings indicate that overexpression of ErbB2 induces BEX2 
expression mediated through the activation of c-Jun signaling (see Figure 3). 
To further examine an association between the overexpression of BEX2 with that of 
ErbB2 and c-Jun, we studied the possibility of ErbB2 induction by c-Jun and BEX2 in 
breast cancer cells. Transient and stable overexpression of c-Jun in MCF-7 line (c-Jun+) 
were carried out using a c-Jun plasmid and both models showed an induction of ErbB2 
expression by c-Jun compared to the control cells (8). Next, the effect of BEX2 on c-Jun-
mediated induction of ErbB2 was determined using a co-transfection of c-Jun and BEX2 
vectors in MCF-7 cells. This showed a 1.5-fold higher ErbB2 level in BEX2+/c-Jun+ cells 
compared to that of control-vector/c-Jun+ line. Furthermore, the overexpression of BEX2 
alone led to a 2.5-fold increase in ErbB2 expression and this effect was reversed with 
the co-transfection of a TAM67 construct. In addition, ChIP studies revealed that the 
effect of BEX2 on ErbB2 expression is mediated through an increase in c-Jun binding to 
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the ErbB2 promoter following BEX2 overexpression. Therefore, BEX2 overexpression 
induces ErbB2 transcription and enhances c-Jun-mediated induction of ErbB2 in breast 
cancer cells.  
Finally, the contribution of BEX2 to the level of ErbB2 overexpression was examined in 
an ErbB2-amplified HCC-1954 cell line. Notably, there was a 25% reduction in ErbB2 
protein level in HCC-1954 cells following BEX2-siRNA silencing compared to the control-
siRNA cells (8).  
Taken together, these findings suggest a functional interplay involving ErbB2, c-Jun and 
BEX2 in breast cancer (see Figure 3). In this process, c-Jun is a transcriptional activator 
of both BEX2 and ErbB2. Furthermore, ErbB2 overexpression results in c-Jun–mediated 
induction of BEX2 expression and BEX2, in turn, enhances c-Jun–mediated 
transcriptional activation of ErbB2. These findings strongly suggest that BEX2 has a 
significant biological role in the ErbB2–c-Jun signaling pathway. 
 
Figure 3. Functional interplay between BEX2, c-Jun and ErbB2 (Green arrow: 
stimulatory effect).  
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2.3 Association of BEX2 expression with clinical and pathological features                           
I have conducted several studies using breast tumor specimens to better understand the 
molecular functions of BEX2 and to identify clinical and pathological features associated 
with BEX2 expression in breast cancer. Initially, these studies were conducted by 
assessing BEX2 mRNA expression on frozen breast tumors (4, 6). Moreover, once my 
group successfully generated and validated a rabbit BEX2 antibody, BEX2 protein 
expression using IHC staining on breast tumors was investigated (7, 8).      
First, we posed the question whether BEX2 expression influences the outcome of 
patients treated with tamoxifen (4). The cases were divided into BEX2 overexpression 
(BEX2+) or BEX2 under-expression (BEX2-) using one of two criteria: (a) log2 ratios 
normalized to the median value on microarrays showing at least 2-fold expression 
difference, and (b) qRT-PCR of samples with < 2-fold expression difference by 
microarray analysis showing CT< -1 standard deviation (SD) or CT> +1 SD of the 
mean. Survival analysis of these cases showed a better disease-free interval in patients 
with BEX2+ (n= 16; 95% confidence interval: 121–161 months) vs. those with BEX2- 
tumors (n= 14; 95% confidence interval: 63–123 months). The better prognosis in 
tamoxifen-treated BEX2+ patients may be due to NF-κB inactivation in these cases (4).  
Another application of tumor samples was to validate our in vitro findings regarding 
cross-talk between BEX2 and the signaling pathways of mitochondrial apoptosis and NF-
κB (6). To achieve this, the association of BEX2 expression with Bcl-2 and p65 NF-κB 
levels was studied in breast tumors using qRT-PCR. A cohort of 24 frozen breast tumors 
was divided into BEX2+ and BEX2- samples with at least 3-fold BEX2 expression 
difference between these two groups. Next, Bcl-2 mRNA expression and the percentage 
of tumor cells with p65 nuclear protein were measured using qRT-PCR and 
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immunofluorescence, respectively. Notably, Bcl-2 expression and p65-nuclear staining 
were significantly higher in the BEX2+ compared to BEX2- samples by 3.7- and 2-fold, 
respectively (p < 0.01). Therefore, BEX2 overexpression is associated with higher levels 
of Bcl-2 expression and p65 NF-κB activation, which supports signaling cross-talk 
demonstrated in our in vitro studies (6).   
In addition, my laboratory examined a potential correlation between BEX2 and c-Jun 
protein levels in breast tumors using IHC staining (7). For this purpose, we first optimized 
and validated a rabbit polyclonal BEX2 antibody for IHC applications and subsequently 
studied the correlation between BEX2 and c-Jun protein levels on 35 primary breast 
tumors. Notably, there was a strong correlation between the percentage of cells that 
showed BEX2 and c-Jun staining in this cohort with a Pearson CC of 0.8 (p< 0.01). This 
strong positive correlation further supports a functional interplay between BEX2 and c-
Jun in breast cancer (7).  
Following the generation of a BEX2 antibody, we examined the expression pattern of 
BEX2 protein in a TMA cohort of 225 breast tissue specimens using IHC (8). Notably, 
BEX2 was not expressed in normal breast tissue. In contrast, approximately 50% of 
breast cancers and 7% of benign breast lesions had BEX2 expression. Furthermore, 
BEX2+ samples showed a diffuse cytoplasmic staining for this protein and there was 
also nuclear staining in tumors that contained a high level of BEX2 (8).  
Subsequently, comparison of the expression of biomarkers between BEX2+ and BEX2- 
breast tumors found an approximately 2-fold higher prevalence of ErbB2 overexpression 
and amplification in BEX2+ compared to BEX2- breast tumors (8). These findings 
indicate a significant association between the overexpression of ErbB2 and BEX2 in 
breast tumors. Furthermore, the percentage of BEX2+ tumors was approximately 4-fold 
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higher in ErbB2+/ph-Jun+ tumors compared to that of ErbB2-/ph-Jun- samples (83% vs. 
22%, p < 0.01). A receiver operating characteristic (ROC) analysis demonstrated that 
BEX2+ staining is a strong predictor for the ErbB2+/ph-Jun+ status in breast tumors with 
an area under curve of 0.81 (p< 0.01). Of note, BEX2+/ErbB2+/ph-Jun+ tumors 
accounted for about 15% of all cases and had a relatively higher p53 and a lower ER 
expression. These data suggest that BEX2+ staining identifies a distinct subset of breast 
tumors with the overexpression of ErbB2 and ph-Jun (8). 
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CHAPTER 3: MOLECULAR FUNCTIONS OF AR IN BREAST CANCER 
3.1 Signaling cross-talk between AR and the ErbB2/ERK pathway                             
ER-negative (ER-) breast tumors constitute around 30% of all cases and in contrast to 
ER-positive (ER+) tumors, where ER signaling has a key biological role, ER- cancer is 
heterogeneous and there is limited knowledge about the pathogenesis of this disease. 
In view of this, I commenced my research on ER- breast cancer during a transition period 
from the University of Cambridge to my independent research laboratory at the 
University of Queensland. Notably, I have continued my work on this topic ever since 
during my faculty position at the University of Queensland (2007 to 2012) and my 
subsequent positions as an Associate Professor and Group Leader at the University of 
Iowa (2012 to 2015) and the University of Hawaii (since 2016).   
My initial findings on the role of androgen receptor (AR) signaling in ER- tumors emerged 
from an additional analysis of expression microarray data (3). This analysis, and the 
related functional data, were published (9). In this study, it was found that 50% of ER- 
tumors were AR+ and 28% were both AR+ and ErbB2+. Notably, the subtype of ER- 
tumors with a “steroid-response” signature that includes AR and ErbB2 genes is termed 
“molecular apocrine” (Farmer et al., 2005). Next, MDA-MB-453 and Sum-190 cell lines 
were characterized as molecular apocrine to conduct functional experiments (9).  
Using molecular apocrine cell lines, a functional cross-talk between the AR and ErbB2 
pathways was demonstrated (9). In this process, the stimulation of AR and ErbB2 
signaling leads to cross-regulation of steroid-response genes; AR, ErbB2, FOXA1, 
XBP1, TFF3 and KLK3. Moreover, AR activation by testosterone enhances the 
proliferation of molecular apocrine cell lines and this effect can be reversed using anti-
androgen flutamide and the anti-ErbB2 AG825 (9). Conversely, the growth stimulatory 
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effect of ErbB2 activation by heregulin can also be inhibited with flutamide, suggesting 
cross-talk between the AR and ErbB2 pathways affecting cell proliferation. Importantly, 
there is a synergy between flutamide and AG825 on cell proliferation and apoptosis, 
indicating a therapeutic advantage in the combined blockage of AR and ErbB2 pathways. 
In addition, as opposed to the physiological transient phosphorylation of extracellular 
signal–regulated kinase (ERK1/2) by testosterone, the addition of ErbB2 inhibition leads 
to persistent phosphorylation of ERK1/2, which negatively regulates the downstream 
signaling and cell growth. These findings suggest cross-talk between AR and ErbB2 in 
molecular apocrine cells involving the ERK pathway (9), (see Figure 4). 
 
Figure 4. AR and FOXA1 interplay with the ErbB2-ERK pathway (Red arrows depict 
stimulatory effects). 
Furthermore, my group investigated cross-talk between FOXA1 and ErbB2 in molecular 
apocrine breast cancer (10). FOXA1 is a notable gene in the molecular apocrine 
signature that has a dual transcriptional regulatory function with the ability to both 
facilitate and restrict key transcription factors such as AR (Sahu et al., 2011). However, 
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there has been limited data available regarding the function of FOXA1 in ER- breast 
cancer.  
Using IHC studies on a TMA cohort, it was observed that ER-/ErbB2+ tumors had 
approximately 2.5-fold higher frequency of FOXA1 overexpression at 72% compared to 
that of ER-/ErbB2- tumors at 30% (10). This led to identification of a cross-regulation 
network between FOXA1 and ErbB2 signaling in ER- breast cancer (10). Two possible 
mechanisms were revealed to explain the association between FOXA1 and ErbB2 
overexpression. In one, ErbB2 signaling genes CREB1 and c-Fos regulate FOXA1 
transcription, and in the other, AP2α regulates the expression of both FOXA1 and ErbB2 
(see Figure 4). Moreover, FOXA1, in turn, regulates the transcription of ErbB2-signaling 
genes. Importantly, this cross-regulation connects FOXA1 to key signaling elements in 
ER- breast cancer such as the ERK-CREB1 axis, NF-κB, and AP2α (10).  
Collectively, this work (9 and 10) identified functional interplay between AR-ErbB2 and 
FOXA1-ErbB2 signaling with therapeutic implications in ER- breast cancer (see Figure 
4).  
3.2 AR as a therapeutic target in ER-negative breast cancer    
In parallel to studies leading to the discovery of a signaling cross-talk between AR and 
the ErbB2-ERK pathway, my group also investigated the therapeutic implications of this 
cross-talk in ER- breast cancer. First, we identified a synergy between AR and ErbB2 
inhibitors in molecular apocrine cells that involved the modulation of ERK 
phosphorylation (9). In view of this finding, the therapeutic efficacy and signaling effects 
of combined treatments with AR and ERK inhibitors were investigated in ER-/AR+ breast 
cancer using in vitro and in vivo models and with the application of complementary 
approaches (11, 12). In one study, we examined the effect of AR blocker flutamide 
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combined with a Cdc25A phosphatase inhibitor PM-20, which persistently 
phosphorylates ERK leading to the inhibition of ERK signaling (11). In another study, the 
effect of a mitogen-activated protein kinase kinase (MEK) inhibitor CI-1040 was 
investigated in combination with flutamide in molecular apocrine cancer (12).  
In vitro experiments were conducted with MDA-MB-453, HCC-1954, and HCC-202 cell 
lines. Drug synergy was assessed by a combination index (CI) method (Zhao et al., 
2004). Firstly, cell viability and apoptosis for the combination therapies were measured 
using MTT and annexin V assays, respectively and secondly the concentrations of each 
monotherapy that resulted in a level of reduction in cell viability and apoptosis similar to 
that observed with each of the combination therapies were identified (11, 12). 
Subsequently, CI values for the combined treatments were calculated as follows: CI = 
[Ca,x/ICx,a] + [Cb,x/ICx,b]. Ca,x and Cb,x are the concentrations of drug A and drug B 
used in combination to achieve x% drug effect and ICx,a and ICx,b are the 
concentrations for single agents to achieve the same effect. A CI less than 1 indicates 
synergy (11, 12).  
For in vivo studies, a xenograft mouse model was developed using MDA-MB-453 cells. 
Flutamide treatment was carried out with 25 mg/60-day slow-release pellets and control 
group received placebo pellets. PM-20 experiments were performed by daily 
intraperitoneal (IP) injections, MEK inhibitor treatment was by daily oral gavage of CI-
1040, and control groups received only solvents by identical administration. 
Based on the results of these studies, synergy between AR and ERK inhibitors was noted 
in molecular apocrine cancer. In this respect, CI values for flutamide combination with 
either PM-20 or CI-1040 were synergistic in all three cell lines at four different dose 
combinations (11, 12). Furthermore, in vivo studies demonstrated that the combination 
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therapies have a significantly higher therapeutic efficacy in reducing tumor growth, 
cellular proliferation and angiogenesis compared to the monotherapies with these agents 
(11, 12). In addition, our data suggested that flutamide and CI-1040 synergize in both 
primary and acquired resistance to ErbB2 inhibitor trastuzumab, the standard targeted 
treatment for ErbB2+ breast cancer. Importantly, the therapeutic effect of combination 
therapy in trastuzumab-resistant cells was associated with the abrogation of increased 
ERK phosphorylation developed in trastuzumab resistance (12). 
Moreover, the effect of combination therapy of flutamide with PM-20 on the regulation of 
ERK signaling targets RSK and Elk-1 was investigated (11). RSK and Elk-1 are activated 
by ERK through phosphorylation and play a key role in ERK-mediated signal 
transduction (Cruzalegui et al., 1999; Doehn et al., 2009). There was a significant 
reduction in the phosphorylation levels of RSK and Elk-1 using different concentrations 
of the combination therapy and this synergistic effect was most evident at concentrations 
of PM-20 that monotherapy had marginal, or no effect, on the phosphorylation of these 
targets (11). These findings demonstrate that the combination of PM-20 and flutamide 
results in significant inhibition of ERK signal transduction that, in turn, can lead to a 
marked reduction in cell viability and growth. 
In summary, our work (11, 12) demonstrates that AR-ERK signaling is a promising 
therapeutic target in molecular apocrine breast cancer. Furthermore, the combination 
therapy with AR and MEK inhibitors may overcome trastuzumab resistance. Therefore, 
a combination therapy strategy with AR and ERK inhibitors may provide an attractive 
therapeutic option for ER-/AR+ breast cancer.  
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3.3 Molecular functions of AR target gene, Prolactin-Induced Protein                                 
The discovery of a cross-talk between AR and the ErbB2-ERK pathway in molecular 
apocrine subtype provided the opportunity to study other functionally important genes in 
this disease. In this respect, my group investigated the transcriptional regulation of the 
top twelve ranked genes in molecular apocrine signature by AR-ERK signaling (13). 
Modulation of AR and ERK signaling in molecular apocrine cell lines was carried out 
using flutamide and CI-1040, respectively. Importantly, we found that Prolactin-Induced 
Protein (PIP) is the most regulated gene by AR-ERK signaling and validated this finding 
using a mouse xenograft model. In addition, using IHC staining, AR+/ER- tumors showed 
a markedly higher expression of PIP (57%) compared to AR-/ER- tumors (16%). Next, 
the mechanism of PIP regulation by AR-ERK signaling was investigated using luciferase 
reporter and ChIP assays. These studies revealed that PIP is a target gene of the ERK-
CREB1 pathway and is induced by AR activation (13). 
I have reviewed the literature on PIP in the context of our studies (14). It is known that 
PIP is one of the most abundant proteins in breast cancer, which has both intracellular 
expression and extracellular secretion (Clark et al., 1999; Wick et al., 1989). The 
available data indicate that PIP is a transcriptional target of AR and prolactin-STAT5 
signaling (Carsol et al., 2002). From a biochemical standpoint, PIP has aspartyl protease 
activity that degrades fibronectin (Caputo et al., 2000). Furthermore, the importance of 
PIP in cell proliferation has been demonstrated by the fact that purified PIP promotes 
growth of breast cancer cells (Cassoni et al., 1995). Despite this information, the 
molecular functions of PIP have remained largely unknown.  
To study the extracellular function of PIP, we examined the effect of PIP expression on 
cell invasion using siRNA-silencing in MDA-MB-453 cells (13). Notably, there was a 
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marked reduction in cell invasion by approximately three-fold following PIP-silencing. It 
is known that the enzymatic degradation of fibronectin releases fragments that bind to 
integrin-β1 and activate the intracellular signaling (Hocking et al., 1998). In view of PIP’s 
ability to degrade fibronectin, we hypothesized that PIP may be required for integrin-β1 
activation. Therefore, the effect of PIP-silencing on integrin-β1 interactions with integrin-
linked kinase 1 (ILK1) and ErbB2 was investigated using co-immunoprecipitation (co-IP) 
assays. Notably, PIP-silencing led to a 70% to 90% reduction in integrin-β1 binding to 
ILK1 and a 90% decrease in ErbB2‐integrin-β1 interaction. In addition, there was nearly 
a complete recovery of integrin-β1 binding to ILK1 and ErbB2 following the addition of 
fibronectin fragments in PIP-silenced cells. Furthermore, PIP expression was necessary 
for the phosphorylation of integrin-β1 signaling targets ERK-CREB1 and Akt (13). These 
findings suggest that PIP expression is necessary for the outside-in activation of integrin-
β1 mediated through the fragmentation of fibronectin (see Figure 5). 
Moreover, IHC staining from a cohort of 210 breast cancers showed that PIP has a high 
level of expression in 85% of tumors, including luminal A (ER+), luminal B (ER+) and 
ER-/AR+ subtypes (15). Therefore, we next carried out a comprehensive investigation 
of PIP molecular functions using siRNA-silencing in a broad group of breast cancer cell 
lines, analysis of expression microarray data and mass spectrometry (MS). These 
studies demonstrated that PIP is required for the progression through G1 phase, mitosis 
and cytokinesis in luminal A, luminal B and molecular apocrine subtypes. In addition, 
defects in mitotic transition and cytokinesis, following PIP-silencing, are accompanied by 
an increase in aneuploidy of breast cancer cells. Furthermore, PIP expression is 
associated with a transcriptional signature enriched with cell cycle genes and it regulates 
key genes in this process including cyclin D1, cyclin B1, BUB1 and FOXM1 (15). 
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To identify the molecular mechanisms involved in PIP-mediated cellular functions, we 
performed MS to identify binding partners for endogenous PIP (15). These studies 
revealed 156 PIP-interacting proteins. Of note, β-tubulin was established as a top PIP-
binding partner in MS and also showed a strong interaction with PIP in co-IP assays (15). 
To test whether PIP binding to β-tubulin has a regulatory effect on microtubule 
polymerization, the effect of PIP-silencing on both polymerized and soluble fractions of 
tubulin was measured. Importantly, the ratio of polymerized to soluble tubulin was 
markedly reduced following PIP-silencing (15). This finding suggests that PIP may be 
required for tubulin polymerization in breast cancer (15). Moreover, MS and co-IP studies 
revealed that PIP interacts with actin-binding proteins including Arp2/3 and is required 
for the inside-out activation of integrin-β1 mediated through Talin-1 (see Figure 5).  
 
Figure 5. PIP regulation of cell cycle and invasion. The identified extracellular and 
intracellular interactions of PIP that can regulate cell cycle and invasion are depicted. 
Fn: fibronectin, Fn-f: fibronectin fragments, ITG: integrin-β1, green arrow: positive 
regulation. This figure is a modified adaptation (15).   
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Another subset of PIP-binding proteins as shown by our MS studies are involved in cell 
adhesion. Therefore, we subsequently examined the effect of PIP on the regulation of 
cell adhesion using PIP-silencing in breast cancer cells (16). These studies revealed that 
PIP expression is necessary for cell adhesion depending on the type of adhesion surface 
and cell line features. For instance, in T-47D and MFM-223 cells, a fibronectin matrix 
induces the baseline adhesion and reverses PIP silencing-mediated reduction of cell 
adhesion. However, in BT-474 cells, the baseline adhesion is not induced by fibronectin 
and PIP-silencing leads to a marked reduction in cell adhesion to both uncoated and 
fibronectin-coated plates. In an attempt to explain an underlying mechanism for PIP 
regulation of cell adhesion, we found that PIP expression is necessary for the formation 
of α-actinin/actin-rich podosomes at the adhesion-sites of breast cancer cells (16). 
Collectively, these studies suggest that PIP has a versatile function in breast cancer, 
resulting from a diverse range of intracellular and extracellular binding partners (see 
Figure 5) and, as a consequence of these interactions, PIP can regulate key processes 
involved in cell cycle such as integrin-β1 activation and microtubule polymerization. 
Importantly, our publications on this topic provide a strong rationale for the tantalizing 
possibility of PIP as a therapeutic target in breast cancer.  
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CHAPTER 4: DISCOVERY OF NOVEL AR TARGET GENES 
4.1 Investigation of AR transcriptional network in breast cancer                                    
The next step in my research on the molecular functions of AR was aimed at the 
identification of an AR-transcriptional network in breast cancer. These studies were 
conducted and published during my faculty positions at the University of Iowa and 
University of Hawaii (17, 18). Traditionally, the studies of AR target genes have been 
limited to a few cell lines and largely concentrated on the application of ChIP-sequencing 
(Ni et al., 2011; Robinson et al., 2011). As a result, key target genes and coregulators of 
AR in breast cancer have remained unknown. To address this shortcoming, an 
integrative genomic analysis was undertaken to discover AR co-expressed genes in 
breast cancer (17, 18). The study of AR co-expressed genes in large genomic datasets 
presents an innovative approach to investigate AR molecular functions and novel target 
genes. This approach ensures that different breast cancer subtypes are appropriately 
represented and that identified genes are highly correlated with AR expression in a large 
non-biased model of this disease.   
As a first step, I analyzed an expression microarray data from a cohort of 52 breast 
cancer cell lines by Neve et al. (Neve et al., 2006). Correlation of AR expression with 
that of every gene in the dataset was calculated (17). This analysis resulted in 
identification of three hundred AR co-expressed genes that had a │CC│ of > 0.5 with AR 
expression. Moreover, functional annotation of the AR co-expressed genes revealed a 
total of thirteen gene ontology functions that significantly associated with the AR-
transcriptional network and had fold enrichments ranging from 1.5 to 33. It is notable that 
the majority of these functional groups were related to cell cycle or cellular metabolism 
(17). The dataset was further analyzed to find genes that have a highly correlated 
expression pattern with AR. For this purpose, a cutoff │CC│ of > 0.6 with AR expression 
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was adopted to identify this gene set; termed “AR-gene signature”. This analysis 
revealed 35 genes in the dataset, excluding the AR gene itself, which correlated with AR 
expression at this cutoff. The set of genes with the strongest positive correlation with AR 
included F7 (gene encoding FVII) and a group of transcriptional regulators such as 
NFATC4 and SPDEF (17). 
Next, the genomic analysis was expanded to refine the AR-gene signature, using an 
additional dataset from 50 breast cancer cell lines (Kao et al., 2009). Notably, out of a 
total of 65 unique cell lines in the combined analysis, 37 cell lines were in common and 
28 cell lines varied between the two cohorts (18). First, a list of highly co-expressed 
genes with AR was identified in each dataset using a cutoff of │CC│ of ≥ 0.6 and then a 
combined “AR-gene signature” was generated by compiling the subset of AR co-
expressed genes in both cohorts. The combined AR-gene signature included a total of 
98 genes, besides AR itself. Importantly, a novel gene, C1orf64 showed the highest 
positive correlation with AR expression in this signature at a CC value of 0.737 (18). 
Furthermore, there were only three other genes in the AR-signature that had a positive 
CC > 0.7 namely, SIDT1, F7 and PATZ1. In addition, approximately 75% of the signature 
genes, which had an overlap between the two datasets, significantly correlated with AR 
expression in both cohorts. This indicates a high level of reproducibility in signature 
genes despite the differences between the two platforms (18).  
The combined AR-gene signature was subsequently examined for possible AR-binding 
sites using publically available AR ChIP-sequencing (ChIP-seq) data in breast cancer 
cells. To achieve this, a list of AR-signature genes with a detectable AR-binding signal 
in their 5 kb promoter regions were identified. Next, an average AR ChIP-seq signal was 
calculated for each promoter binding detected in the signature genes. A total of 31 genes 
in the AR-signature, including C1orf64 and F7, had detectable AR ChIP-seq signals (18). 
30 
 
It is notable that 30 out of 57 positively co-expressed genes in the AR-signature had 
ChIP-seq-detected AR binding. These data suggest a positive coexpression pattern with 
AR in combination with a detectable AR binding in ChIP-seq can potentially predict the 
transcriptional targets of AR. Importantly, these studies led me to investigate F7 and 
C1orf64 as novel AR target genes in breast cancer. 
4.2 Coagulation Factor VII is an AR target gene                                                             
The association between FVII and AR expression was subsequently investigated using 
IHC in a TMA cohort of 209 breast tumors (17). These studies revealed that AR staining 
is higher in tumors with FVII scores of 2 to 3 compared to those with lower FVII scores 
(0 to 1) at 52% and 36%, respectively (p<0.01). In addition, a ROC analysis was applied 
to predict FVII expression scores based on the positive or negative status of AR staining 
in breast tumors. Notably, AR status could reliably predict FVII expression with an area 
under the curve of 0.664 (17). These findings suggest a positive association between 
the protein levels of FVII and AR in breast tumors. 
In view of the highly correlated expression pattern between AR and FVII, the possibility 
of AR-mediated transcriptional regulation of F7 was examined in breast cancer cells. In 
this respect, AR+/ER+ cell line T-47D and AR+/ER- line MFM-223 were tested to assess 
the effect of AR activation by dihydrotestosterone (DHT) on F7 transcription (17). 
Notably, DHT treatment significantly increased F7 expression by 1.5 to 2.5-fold (p< 0.01), 
indicating that AR activation results in an induction of F7 transcription in breast cancer 
cells. Moreover, in agreement with the F7 transcription data, FVII was induced at the 
protein level following AR activation and there were several putative AR binding sites in 
the F7 promoter region from bioinformatics analysis (17). To investigate whether F7 is a 
direct AR target gene, ChIP assays were performed using an AR antibody and primer-
sets in the 2 kb region of F7 promoter. Importantly, ChIP data suggested that AR binds 
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to the F7 promoter in a region close to the ATG start codon. This suggests AR as a direct 
transcriptional activator of F7 in breast cancer (17).  
Furthermore, the effect of AR-mediated induction of FVII on the activity of this protein 
was assessed by measuring the conversion of FX to FXa (17). T-47D cell line was 
treated with either DHT or vehicle control for 48h followed by cell lysate extraction and 
measurement of Tissue Factor (TF)-FVII activity. To assess the contribution of 
endogenous FVII to the overall TF activity, assays were carried out for each experiment 
in the absence (lysate) or presence of exogenous FVII (lysate + FVII). Next, the ratio of 
TF-FVII activity in each cell lysate was calculated relative to that of lysate + exogenous 
FVII and compared between the DHT-treated and control groups. Notably, AR activation 
significantly increased the ratio of endogenous TF-FVII activity/total TF activity from 0.57 
in the control group to 0.80 in the DHT-treated cells (p< 0.03). This indicates that AR 
activation induces FVII activity in breast cancer cells (17). 
Taken together, we can propose a model for the regulation of ectopic FVII expression by 
AR in breast cancer cells. In this model, AR induces FVII expression and leads to an 
increased activity of FVIIa/TF complex that, in turn, converts FX to FXa. This activation 
of coagulation FVII by AR provides a novel mechanism for the transcriptional regulation 
of ectopic FVII expression in cancer. Importantly, this study implicates a potential role 
for AR signaling in the pathobiology of thromboembolic events and the regulation of 
FVII/TF signaling pathway in breast cancer (17). 
4.3 Discovery of a novel protein, C1orf64 (SRARP), as an AR coregulator                    
Genomic data suggested a novel gene, C1orf64, is highly co-expressed with AR in 
breast cancer and there is a detectable AR binding to the C1orf64 promoter by ChIP-
seq. Therefore, I investigated C1orf64 as an AR target gene in breast cancer (18). The 
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transcriptional studies were carried out in breast cancer cell lines T-47D (ER+/AR+) and 
MFM-223 (ER-/AR+). Notably, DHT-induced AR activation led to a marked reduction in 
C1orf64 expression by 2 to 10-fold compared to controls using qRT-PCR (p< 0.01). 
Conversely, AR-siRNA silencing increased C1orf64 expression by 3 to 4-fold in breast 
cancer cells (p< 0.01). Furthermore, DHT treatment of T-47D and MFM-223 cells 
markedly reduced C1orf64 protein levels by 3.3 to 6.7-fold using western blot analysis 
(18). These findings suggest that AR activation has a profound repressive effect on 
C1orf64 expression in AR+ breast cancer cells.   
To examine whether C1orf64 is a direct AR target gene, ChIP assays were used to 
assess the promoter region of this gene in T-47D and MFM-223 cell lines (18). A total of 
six primer sets were employed for the 2 kb promoter region of C1orf64 to generate 
amplicons using qRT-PCR. ChIP assays revealed a significant enrichment by 80-fold 
(p< 0.01) for AR binding to an amplicon located at -1648 to -1527 bp region on the 
C1orf64 promoter. This strongly suggests that C1orf64 is a direct transcriptional target 
of AR in breast cancer. 
To further investigate the association between C1orf64 and AR in breast cancer, C1orf64 
co-expressed genes were assessed in primary and metastatic breast tumors (18). In this 
respect, two large cohorts were analyzed using ONCOMINE database (Bos et al., 2009; 
Grossman et al., 2016; Rhodes et al., 2004). Co-expression analysis in these datasets 
showed that AR is highly correlated with C1orf64 expression in both primary and 
metastatic breast tumors with CC values of 0.667 and 0.573, respectively (18). 
Furthermore, the association studies with clinical and pathological features in breast 
cancer demonstrated that C1orf64 expression is relatively higher in lobular histology, 
lower grade and ER+ tumors (18).  
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Moreover, functional studies identified an interplay between AR and C1orf64 in breast 
cancer (18). In this interplay, AR activation directly represses C1orf64 transcription and 
C1orf64, in turn, interacts with AR as a corepressor and negatively regulates AR-
mediated induction of PIP expression (see Figure 6). This negative regulation of AR is 
further supported by the fact that C1orf64 has a profound repressive effect on the AR 
luciferase reporter activity in breast cancer cells (18). In addition, the corepressor effect 
of C1orf64 results in a reduction of AR binding to the PIP promoter using ChIP assays. 
Another aspect of this interplay involves cross-talk between the AR and ER signaling in 
ER+ cells. In this respect, AR activation abrogates ER-mediated induction of 
progesterone receptor (PGR). In contrast, C1orf64 is necessary for PGR expression; 
therefore, the repression of C1orf64 by AR has an inhibitory effect on the positive 
regulatory function of C1orf64 on ER activity (see Figure 6).  
Of note, a combination of bioinformatics and biochemical studies revealed that C1orf64 
is a phosphothreonine protein and an interacting partner of 14-3-3 protein in breast 
cancer cells (18). In addition, C1orf64 is predicted to be phosphorylated by Casein 
Kinase 1 at a T152 site adjacent to a 14-3-3 interacting motif (18). 14-3-3 is a chaperone, 
and scaffolding protein, that binds serine/threonine-phosphorylated residues and 
regulates key proteins involved in various cellular processes such as intracellular 
signaling and gene transcription (Mackintosh, 2004; Zilliacus et al., 2001). However, 
there was no direct interaction between the endogenous 14-3-3 and AR in breast cancer 
cells (18). In view of these points, a plausible mechanism for the C1orf64 coregulatory 
effect on AR may involve a competition with 14-3-3 binding to this receptor or acting as 
a scaffolding protein in a complex that includes 14-3-3 and AR (see Figure 6).  
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Figure 6. The negative interplay between AR and C1orf64 in breast cancer (18). Red 
arrows denote a stimulatory effect and black lines indicate a repressive function. ARE: 
androgen response element.  
In summary, AR activation directly represses C1orf64 transcription in breast cancer cells 
and C1orf64, in turn, interacts with AR as a corepressor and negatively regulates AR-
mediated transcriptional activities (see Figure 6). Importantly, C1orf64 interacts with the 
chaperone protein 14-3-3, presenting an underlying mechanism for the molecular 
functions of C1orf64 by modulation of the chaperone activity of this key protein. 
Therefore, there is an interplay between C1orf64 and AR with significance in the biology 
of breast cancer. Following the discovery of C1orf64 as a novel AR coregulator, this was 
communicated to HUGO Gene Nomenclature Committee (HGNC) for updating the 
nomenclature of this gene. As a result, my proposal for updating the nomenclature of 
C1orf64 to “Steroid Receptor Associated and Regulated Protein” (SRARP) was accepted 
by HGNC in July 2017. Moreover, my publication has been featured by the Universal 
Protein (UniProt) Consortium (http://www.uniprot.org) with respect to the biological 
function and nomenclature of SRARP. 
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CHAPTER 5: IMPACT AND APPLICATIONS                                                                 
In this commentary, I have discussed my publications on the molecular functions of AR 
and BEX2 in breast cancer. It is notable that these publications have made significant 
contributions to the fields of cancer genomics, cancer biology and experimental 
therapeutics with broad applications in breast cancer and other malignancies.   
Methodologies outlined in chapter 1 have documented applications for RNA purification 
and expression microarray analysis in various fields such as cancer genomics, nucleic 
acid amplification and developmental biology (Coussens et al., 2007; Lawson et al., 
2010; Suslov and Steindler, 2005). Furthermore, the presented microarray dataset in 
breast tumors has been highly cited in genomic and cancer biology studies over the past 
decade (3). For example this study has been applied in meta-analysis expression 
profiling of breast cancer (Gyorffy and Schafer, 2009), discovery of molecular 
mechanism for C/EBPδ activity (Pawar et al., 2010), and identification of predictive 
biomarkers for distant recurrence in breast cancer (Aleskandarany et al., 2015). 
Furthermore, my publications on the pro-oncogenic function of BEX2 in breast cancer 
and the pathways involved in this process opened up a new field of research and, in 
particular, impacted the study of BEX2 in brain tumors. It is notable that an initial study 
had demonstrated a possible tumor suppressor function for BEX2 in glioblastoma, an 
aggressive brain cancer (Foltz et al., 2006). However, our findings in breast cancer 
impacted the subsequent studies on BEX2 that suggested a pro-oncogenic function for 
this gene in brain malignancies. In this respect, data by Le Mercier et al. and Zhou et al. 
showed that BEX2 promotes cell migration and invasion in oligodendroglioma and 
glioblastoma brain tumor cells (Le Mercier et al., 2009; Zhou et al., 2012b). In addition, 
there is evidence suggesting that β-catenin is involved in BEX2-mediated induction of 
cell invasion and migration of glioma cells (Nie et al., 2015).  
36 
 
In fact, publications (4-8) have contributed to the subsequent studies into the role of 
BEX2 in apoptosis and proliferation of glioma cells and have revealed that many of our 
findings regarding BEX2 function are reproducible in glioma (Meng et al., 2014; Seznec 
et al., 2010; Zhou et al., 2012a). For instance, siRNA-silencing of BEX1 and BEX2 
sensitizes glioma cells to apoptosis mediated by a dominant-positive variant of p53 
(Seznec et al., 2010). In addition, BEX2 expression protects glioma cells against 
apoptosis mediated through the JNK pathway and is required for glioma cell proliferation 
through the NF-κB p65 (Meng et al., 2014; Zhou et al., 2012a). It is notable that, besides 
glioma, our findings on BEX2 function have been validated in other cancers. Most 
recently, it has been shown that BEX2 promotes cell proliferation through the JNK/c-Jun 
pathway and regulates JNK/c-Jun phosphorylation in colorectal cancer (Hu et al., 2017). 
In addition, another group has shown that BEX2 expression is required for cell 
proliferation and Hepatitis B Virus-mediated development of hepatocellular carcinoma 
(Huang et al., 2017). Therefore, our BEX2 work has significantly contributed to the 
advancement of our understanding about this gene in malignancies.  
Moreover, our initial articles on AR signaling have made an original contribution to the 
characterization of molecular apocrine subtype and have been widely cited in studies 
about the pattern of AR expression in ER- breast cancer (Collins et al., 2011; Niemeier 
et al., 2009; Park et al., 2010). In addition to AR, our findings on the steroid-response 
signature have impacted the research conducted on other genes in this signature. For 
instance, publications on FOXA1 interplays with AR and ErbB2 signaling (9, 10), have 
contributed to the subsequent studies on FOXA1 function in basal subtype and ErbB2-
induced breast cancers (Bernardo et al., 2013; Hodgson et al., 2013). Another example 
is the TFF3 gene, a member of the steroid-response signature (9), which was later shown 
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to be involved in breast cancer development and metastasis (Kannan et al., 2010; 
Pandey et al., 2014).  
Importantly, the publications on AR cross-talk with ErbB2 signaling have impacted the 
emerging application of AR as a therapeutic target in the management of ER-/AR+ breast 
cancer (9, 11, and 12). In this respect, a phase II trial of bicalutamide has shown 
therapeutic efficacy and minimal toxicity in metastatic AR+/ER- breast cancer patients 
(Gucalp et al., 2013). Additional trials are ongoing that will address the clinical 
applications of AR inhibition in breast cancer. For example, there is currently an ongoing 
study to assess the efficacy and safety of AR inhibitor enzalutamide with ErbB2 inhibitor 
trastuzumab in patients with ErbB2+/AR+ metastatic or locally advanced breast cancer 
(NCT02091960). However, there is a need for further combination therapy trials to 
examine our preclinical findings that demonstrated a synergy between the inhibitors of 
AR and ERK signaling in ER-/AR+ breast cancer. 
Finally, our work on AR target genes have contributed to a number of research fields. In 
this respect, we demonstrated that PIP regulates invasion, cell adhesion and cell cycle 
(13-16). Besides their impact on breast cancer research, these publications have been 
cited in other fields of research such as studies on PIP-mediated regulation of immune 
response (Li et al., 2015; Xiang et al., 2016). In addition, the identification of novel AR 
target genes provides a major advancement in the field of AR signaling with broader 
implications (17, 18). For instance, following the discovery of F7 as an AR co-expressed 
and target gene in breast cancer, a similar coexpression pattern between AR and F7 has 
been reported in prostate cancer (Shahbazi et al., 2016). Most recently, the publication 
of C1orf64 as a novel AR coregulator and discussions with HGNC resulted in updating 
the nomenclature of this gene to SRARP and opened a novel field of research in cancer 
biology.  
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